April 24, 2009 - Theravance, Inc. announced today that the U.S. FDA accepted as complete for review Theravance's response to the February 2009 Complete Response letter, which outlined requirements for approval of telavancin for the treatment of complicated skin and skin structure infections.
The details can be read here.
No comments:
Post a Comment